Tweet
Upgraded Illumina HiSeq Chemistry
I recently heard a rumor that Illumina is about to introduce a new chemistry that will allow for 2x300bp output. I can't seem to find any more information about it and was wondering if any one else had heard the same thing. I am very interested in learning more about this and would like any information on the topic.
-
-
They have been sitting at 100bp reads for a long time. I would not expect a jump to 300 any time soon. You might have heard about 2x150, or 300 cycle hi seq chemistry.
300bp reads would most likely be on the Miseq first due to the small cycle time. -
They've recently mentioned 2x300bp for the MiSeq in the 2nd half of 2013.Comment
-
MiSeq
With the upgrade they are selling 500 cycle kits to run a 2x250 base run (with index). Haven't run it yet because we are using up our stock of v1 kits first.Comment
-
-
MiSeq not HiSeq
This is for the MiSeq right now-not the HiSeq. I don't think the HiSeq 2500 is going beyond 2 x 150Originally posted by snetmcom View PostComment
-
this thread is about hiseq. which is why i found your note confusing.Originally posted by kwaraska View PostComment
-
FWIW, at the recent Boston Illumina Users' Group Meeting in October, my memory is that 2x150 in rapid mode on the 2500 is the only longer chemistry on HiSeq that was discussed; when queried about 2x150 in standard mode or longer than 2x150 in rapid mode, the Illumina reps were not encouraging speculation that anything like that would be available soon.Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment